The applications of B-type natriuretic peptide measurement in the intensive care unit

Current Opinion in Critical Care

Volumn 11, Issue 5, 2005, Pages 406-412

  McLean, Anthony S ^a   Huang, Stephen J ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

Author keywords

B type natriuretic peptide; Cardiac dysfunction; Intensive care; Sepsis

Indexed keywords

BRAIN NATRIURETIC PEPTIDE;

HEART DISEASE; HEART FAILURE; HOSPITAL CARE; HUMAN; INTENSIVE CARE; MEASUREMENT; MORTALITY; PREDICTION; PROGNOSIS; REVIEW; SCREENING; SEPTIC SHOCK;

BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; CRITICAL ILLNESS; HUMANS; INTENSIVE CARE; INTENSIVE CARE UNITS; NATRIURETIC PEPTIDE, BRAIN;

EID: 26944453179     PISSN: 10705295     EISSN: 15317072     Source Type: Journal    
DOI: 10.1097/01.ccx.0000176695.92883.87     Document Type: Review

References (50)

1. Sudoch T, Kangawa K, Minamino N. A new natriuretic peptide in porcine brain. Nature 1988; 332:78-81.
2. Saper CB, Hurley KM, Moga MM, et al. Brain natriuretic peptides: Differential localization of a new family of neuropeptides. Neurosci Lett 1989; 96:29-34.
3. Hystad ME, Geiran OR, Attramadal H, et al. Regional cardiac expression and concentration of natriuretic peptides in patients with severe chronic heart failure. Acta Physiol Scand 2001; 171:395-403.
4. Luchner A, Stevens TL, Borgeson DD, et al. Differential atrial and ventricular expression of myocardial BNP during evolution of heart failure. Am J Physiol 1998; 274:H1684-H1689.
5. Yasue H, Yoshimura M, Sumida H, et al. Localisation and mechanism of secretion of B-type natriuretic peptide in comparison with those of A-type natriuretic peptide in normal subjects and patients with heart failure. Circulation 1994; 90:195-203.
6. Suttner SW, Boldt J. Natriuretic peptide system: physiology and clinical utility. Curr Opin Crit Care 2004; 10:336-341. This is a succinct review of the physiology of the natriuretic peptide system.
7. Nakagawa O, Ogawa Y, Itoh H, et al. Rapid transcriptional activation and early mRNA turnover of brain natriuretic peptide in cardiocyte hypertrophy. Evidence for brain natriuretic peptide as an 'emergency' cardiac hormone against ventricular overload. J Clin Invest 1995; 96:1280-1287.
8. Sawada Y, Suda M, Yokoyama H, et al. Stretch-induced hypertrophic growth of cardiocytes and processing of B-type natriuretic peptide are controlled by proprotein-processing endopretease furin. J Biol Chem 1997; 272: 20545-20554.
9. Suga S, Nakao K, Hosoda K, et al. Receptor selectivity of natriuretic peptide family, ANP, BNP and CNP. Endocrinology 1992; 130:229-239.
10. McLean AS, Tang B, Nalos M, et al. Increased B-type natriuretic peptide (BNP) level is a strong predictor for cardiac dysfunction in the intensive care unit patients. Anaesth Intensive Care 2003; 31:21-27.
11. McLean AS, Huang SJ, Nalos M, et al. The confounding effects of age, gender, serum creatinine, and electrolyte concentrations on plasma B-type natriuretic peptide concentrations in critically ill patients. Crit Care Med 2003; 31: 2611-2618.
12. Loke I, Squire IB, Davies JE, Ng LL. Reference ranges for natriuretic peptides for diagnostic use are depending on age, gender and heart rate. Eur J Heart Fail 2003; 5:599-606.
13. Gerbes AF, Dagnino L, Nguyen T, Nemer M. Transcription of brain natriuretic peptide and atrial natriuretic peptide genes in human tissues. J Clin Endocrinol Metab 1994: 78:1307-1311.
14. Akiba T, Tachibana K, Togashi K, et al. Plasma human brain natriuretic peptide in chronic renal failure. Clin Nephrol 1995; 44:S61-S64.
15. Takami Y, Horio T, Iwashima Y, et al. Diagnositc and prognostic value of plasma brain natriuretic peptide in non-dialysis-dependent CRF. Am J Kidney Dis 2004; 44:420-428. The study investigated the diagnostic value of BNP for left ventricular overload in non-dialysis chronic renal failure patients; it also sought to clarify whether BNP value is independent of severity of renal dysfunction.
16. Wahl HG, Graf S, Renz H, Fassbinder W. Elimination of the cardiac natriuretic peptides B-type natriuretic peptide (BNP) and N-Terminal proBNP by hemodialysis. Clin Chem 2004; 50:1071-1074. This study demonstrated that both BNP and NT-proBNP were eliminated during hemodialysis. The elimination depends on the type of dialysis membrane chosen.
17. Luchner A, Burnett JC Jr, Jougasaki M, et al. Augmentation of the cardiac natriuretic peptides by beta-receptor antagonism: evidence from a population-based study. J Am Coll Cardiol 1998; 32:1839-1844.
18. Yoshimura M, Yasue H, Tanaka H, et al. Responses of plasma concentrations of A type natriuretic peptide and B type natriuretic peptide to alacepril, an angiotensin-converting enzyme inhibitor, in patients with congestive heart failure. Br Heart J 1994; 72:528-533.
19. McLean AS, Poh G, Huang SJ. The effects of acute fluid loading on plasma B-type natriuretic peptide levels in a septic shock patient. Anaesth Intensive Care 2005; 33:528-530. This interesting case study demonstrated the effects of fluid loading on the right ventricular size and BNP levels in a severe septic patient.
20. Cowie MR, Struthers AD, Wood DA, et al. Value of natriuretic peptides in assessment of patients with possible new heart failure in primary care. Lancet 1997; 350:1349-1353.
21. Maisel AS, Krishnaswamy P, Nowak RM, et al. Rapid measurement of B-type natriuretic peptide assay in emergency diagnosis of heart failure. N Engl J Med 2002; 347:161-167.
22. Maisel AS, McCord J, Nowak RM, et al. Bedside B-type natriuretic peptide in the emergency diagnosis of heart failure with reduced or preserved ejection fraction. Results from the Breathing Not Properly Multinational Study. J Am Coll Cardiot 2003; 41:2010-2017.
23. McCullough PA, Nowak RM, McCord J, et al. B-type natriuretic peptide and clinical judgement in emergency diagnosis of heart failure: analysis from Breathing Not Properly (BNP) Multinational Study. Circulation 2002; 106: 416-422.
24. Maisel A, Hollander JE, Guss D, et al. Primary results of the Rapid Emergency Department Heart Failure Outpatient Trial (REDHOT). J Am Coll Cardiol 2004; 44:1328-1333. The authors describe a multicenter trial of 464 patients who attended the emergency department with shortness of breath. BNP concentrations did not correlate with the New York Heart Association class, but were a strong predictor for 90-day mortality.
25. Rhodes A, Tilley R, Barnes S, et al. A prospective study into the use of NT-proBNP measurements in critically ill patients. Clin Intensive Care 2004; 15:31-36. NT-proBNP was measured in 93 consecutive ICU patients and the levels were elevated in all of them. Sepsis and cardiac dysfunction were the main contributors to the elevated BNP levels. Admission BNP can predict hospital mortality.
26. Cuthbertson BH, Patel RR, Croal BL, et al. B-type natriuretic peptide and the prediction of outcome in patients admitted to intensive care. Anaesthesia 2005; 60:16-21. Admission BNP concentrations were higher in patients with sepsis and septic shock. BNP did not predict outcome after intensive care.
27. Witthaut R, Busch C, Fraunberger P, et al. Plasma atrial natriuretic peptide and brain natriuretic peptide are increased in septic shock: impact of interleukin-6 and sepsis-associated left ventricular dysfunction. Intensive Care Med 2003; 29:1696-1702.
28. Chapentier J, Luyt C-E, Fulla Y, et al. Brain natriuretic peptide: A marker of myocardial dysfunction and prognosis during severe sepsis. Crit Care Med 2004; 32:660-665. This study measured daily BNP levels for 4 consecutive days in patients with severe sepsis. The day 2 to 4 BNP levels were higher in patients with myocardial dysfunction. Patients who died exhibited higher day 2 and 3 BNP concentrations.
29. Roch A, Allardet-Servent J, Michelet P, et al. NH2 terminal pro-brain natriuretic peptide plasma level as an early marker of prognosis and cardiac dysfunction in septic shock patients. Crit Care Med 2005; 33:1001-1007. BNP was increased in septic shock patients and was a marker for cardiac dysfunction. It also predicted ICU mortality.
30. Etsuo M, Hirofumi Y, Michihiro Y, et al. Increased plasma levels of brain natriuretic peptide in patients with acute myocardial infarction. Circulation 1993; 88:822-921.
31. Murdoch DR, McDonagh TA, Byrne J, et al. Titration of vasodilator therapy in chronic heart failure according to plasma brain natriuretic peptide concentration: randomized comparison of the hemodynamic and neuroendrocrine effects of tailored versos empirical therapy. Am Heart J 1999; 138: 1126-1132.
32. Troughton RW, Frampton CM, Yandle TG, et al. Treatment of heart failure guided by plasma ammoterminal brain natriuretic peptide (N-BNP) concentrations. Lancet 2000; 355:1126-1130.
33. Latini R, Masson S, Anand I, et al. Effects of Valsartan on circulating brain natriuretic peptide and norepinephrine in symptomatic chronic heart failure. The Valsartan Heart Failure Trial (Val-HeFT). Circulation 2002; 106:2454-2458.
34. Connors AF Jr, Speroff T, Dawson NV, et al. The effectiveness of right heart catheterization in the initial care of critically ill patients. JAMA 1996; 276: 889-897.
35. Lubein E, DeMaria A, Krishnaswamy P, et al. Utility of B-natriuretic peptide in detecting diastolic dysfunction. Comparison with Doppler velocity recordings. Circulation 2002; 105:595-601.
36. Dokainish H, Zoghbi WA, Lakkis NM, et al. Optimal non-invasive assessment of left ventricular filling pressures. A comparison of tissue Doppler echocardiography and B-type natriuretic peptide in patients with pulmonary artery catheters. Circulation 2004; 109:2432-2439. This study compares the echocardiographic E/Ea ratio and BNP in predicting pulmonary capillary wedge pressure >15 mmHg.
37. Kazanegra R, Cheng V, Garcia A, et al. A rapid test for B-type natriuretic peptide correlates with falling wedge pressures in patients treated for decompensated heart failure: A pilot study. J Card Fail 2001; 7:21-29.
38. Tung RH, Garcia C, Morss AM, et al. Utility of B-type natriuretic peptide for the evaluation of intensive care unit shock. Crit Care Med 2004; 32: 1643-1647. The BNP concentrations between survivor and non-survivor were compared in patients with shock. BNP concentrations did not correlate with cardiac index or pulmonary artery occlusion pressure.
39. McLean AS, Huang SJ. B-type natriuretic peptide to assess cardiac function in the critically ill. In: Yearbook of Intensive Care and Emergency Medicine 2005. Vincent J-L (ed). Heidelberg: Springer-Verlag; 2005. pp 151-160. This is a comprehensive and critical review on the background and use of BNP in assessing cardiac function in the critically ill.
40. Wallen T, Landahl S, Hedner T, et al. Brain natriuretic peptide predicts mortality in the elderly. Heart 1997; 77:264-267.
41. Wang TJ, Larson MG, Levy D, et al. Plasma natriuretic peptide levels and the risk of cardiovascular events and death. N Engl J Med 2004; 350:655-663.
42. Doust JA, Pietrzak E, Dobson A, Glasziou PP. How well does B-type natriuretic peptide predicts death and cardiac events with heart failure: systematic review. BMJ 2005; 330:625-633. This is a systematic and comprehensive meta-analysis of the clinical studies performed over the last 10 years. It compared the value of BNP with other traditional prognostic indicators such as New York Heart Association class, serum creatinine, and left ventricular ejection in the prediction of death at all stages of heart failure.
43. Rogues F, Nashef SAM, Gauducheau E, et al. Risk factors and outcome in European cardiac surgery: Analysis of the EuroSCORE multi-national database. Eur J Cardiothorac Surg 1999; 15:816-823.
44. Chello M, Mastroroberto R, Perticone F, et al. Plasma levels of atrial and brain natriuretic peptide as indicators of recovery of left ventricular systolic functon after coronary artery bypass. Eur J Cardiothorac Surg 2001; 20:140-146.
45. Kerbaul F, Collart F, Oddoze C, et al. Increased plasma levels of pro-brain natriuretic peptide in patients with cardiovascular complications following off-pump coronary artery surgery. Intensive Care Med 2004; 30:1799-1806.
46. Berendes E, Schmidt C, Van Aken H, et al. A-type and B-type natriuretic peptides in cardiac surgical procedure. Anesth Analg 2004; 98:11-19.
47. Cuthbertson BH, McKeown A, Croal BL, et al. Utility of B-type natriuretic peptide in predicting the level of peri-and post-operative cardiovascular support required after coronary artery bypass grafting. Crit Care Med 2005; 33: 437-442.
48. Mair J, Friedl W, Thomas S, Puschendorf B. Natriuretic peptides in assessment of left-ventricular dysfunction. Scand J Clin Lab Invest 1999; 59: 132-142.
49. McCullough PA, Omland T, Maisel AS. B-type natriuretic peptide: a diagnostic breakthrough for clincians. Rev Cardiovasc Med 2003; 4:72-80.
50. Wu AHB, Smith AC, Mather JF, et al. Biological variation for NT-pro-and B-type natriuretic peptides and implications for therapeutic monitoring of patients with congestive heart failure. Am J Cardiol 2003; 92:428-431.